DXCM vs RMD: stock comparison and AI forecast
Dexcom Inc (DXCM) and Resmed Inc (RMD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DXCM Dexcom Inc
- Market Cap
- $31.05B
- P/E Ratio
- 29.9x
- Size
- large-cap
- AI Forecast
RMD Resmed Inc
- Market Cap
- $33.17B
- P/E Ratio
- 20.9x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DXCM and RMD have similar market capitalizations ($31.05B and $33.17B).
- RMD trades at 20.9 times trailing earnings, DXCM at 29.9 times.
- RMD turns 27.8% of its revenue into net income, against 19.4% for DXCM.
- DXCM carries 1.46 times debt per unit of equity, against 0.38 times for RMD.
- RMD yields 1.08% in dividends; DXCM pays none.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DXCM | RMD |
|---|---|---|
| Market Cap | $31.05B | $33.17B |
| P/E Ratio | 29.92x | 20.94x |
| P/B Ratio | 12.25x | 5.58x |
| Dividend Yield | – | 1.08% |
| EPS | $2.75 | $10.98 |
| Book Value/Share | $6.72 | $41.23 |
| Revenue/Share | $13.53 | $39.74 |
| FCF/Share | $2.91 | $11.15 |
Profitability & Margins
| Metric | DXCM | RMD |
|---|---|---|
| ROE | 39.1% | 26.8% |
| ROA | 15.9% | 19.4% |
| ROIC | 30.7% | 27.5% |
| Gross Margin | 63.4% | 61.1% |
| Operating Margin | 24.0% | 33.0% |
| Net Margin | 19.4% | 27.8% |
| EBT Margin | 24.7% | 35.1% |
| Tax Rate | 21.5% | 20.8% |
Financial Health
| Metric | DXCM | RMD |
|---|---|---|
| Current Ratio | 1.74x | 2.65x |
| Quick Ratio | 1.40x | 1.88x |
| D/E Ratio | 1.46x | 0.38x |
| Financial Leverage | 2.46x | 1.38x |
| Interest Coverage | 155.8x | 99.0x |
| Working Capital | $1.66B | $2.18B |
Cash Flow
| Metric | DXCM | RMD |
|---|---|---|
| Operating Cash Flow | $1.41B | $1.77B |
| Free Cash Flow | $1.10B | $1.61B |
| Capital Spending | -$316M | -$162M |
| OCF Growth YoY | -2.3% | -6.0% |
| FCF Growth YoY | 3.4% | -9.0% |
| FCF/Sales | 21.5% | 28.1% |
| CapEx/Sales | 6.2% | 2.8% |
Operational Efficiency
| Metric | DXCM | RMD |
|---|---|---|
| Asset Turnover | 0.82x | 0.70x |
| Receivables Turnover | 4.3x | 5.9x |
| Inventory Turnover | 2.4x | 2.2x |
| Fixed Assets Turnover | 3.3x | 9.5x |
| Days Sales Outstanding | 85 days | 62 days |
| Days Inventory | 151 days | 167 days |
| Payables Period | 404 days | 52 days |
| Cash Conversion Cycle | -168 days | 177 days |
Income Statement
| Metric | DXCM | RMD |
|---|---|---|
| Total Revenue | $5.10B | $5.73B |
| Operating Income | $1.22B | $1.89B |
| Net Income | $991M | $1.59B |
| R&D Expense | $608M | $394M |
| SG&A Expense | $1.41B | $1.18B |
| Cost of Goods Sold | $1.87B | $2.23B |
Dividend & Shareholder Information
| Metric | DXCM | RMD |
|---|---|---|
| Dividends Per Share | – | $2.47 |
| Payout Ratio | – | 22.5% |
| Shares Outstanding | 377M | 144M |
| Net Income Growth | 37.5% | 10.8% |
| EPS Growth | 54.5% | 12.4% |
DXCM vs RMD: stock comparison and AI forecast
Which is bigger, DXCM or RMD?
DXCM and RMD have similar market capitalizations ($31.05B and $33.17B).
Which is cheaper on earnings, DXCM or RMD?
RMD trades at 20.9 times trailing earnings, DXCM at 29.9 times.
Which one does Intratio's AI model rank higher, DXCM or RMD?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.